Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Regeneron Pharmaceuticals Analyst Ratings
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125
Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN)
Regeneron Pharmaceuticals Analyst Ratings
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating